about
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsThe complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infectionViability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsEquivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapySafer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough?TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.Low bone mineral density among HIV-infected patients in Brazil.Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss.Endocrinological aspects of HIV infection.Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
P2860
Q33669829-5E1F6D66-09A3-4B73-B853-669DC77745AEQ33705883-EE1F8822-6AA3-4496-8E2F-492F6018A1CDQ34506677-F7530AB8-15DD-4E6F-8E3E-15FD9C034239Q36275141-BA9E7393-41C0-47BE-94A7-1E9EAD70AEB4Q37354871-17BE7300-2CD7-4572-9EA5-FE433E72FC4FQ37519831-80E855F0-5CE8-4EBB-9E0F-041EA98F3C10Q37604553-C96C0354-FD6A-4331-81F7-A9FA2339BB65Q38911526-3DCBCCF5-8411-4929-B092-FF49165E2719Q40676324-8F05F327-9B37-4486-A2C7-DC3A663CC443Q43201412-50FAD705-22F8-4409-8A15-8F12ECC520DDQ43923848-5CE15A81-CAE6-4C48-AF9D-6B7C040E8DC7Q46837128-7EA0B4EC-AE3E-4F94-A99A-F9DEB1B66366Q47142805-FAD42BCB-9CB3-4096-B599-C3B8806F609FQ47194100-8F87CE50-6EA0-4A47-ABD3-96C6982093B8Q47219853-14CCA977-BF47-4480-A0FE-1B389741B0B4Q47560453-EA44AD23-B85D-4973-AF18-38545F98DE69
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bone health and human immunodeficiency virus infection.
@en
type
label
Bone health and human immunodeficiency virus infection.
@en
prefLabel
Bone health and human immunodeficiency virus infection.
@en
P2093
P2860
P356
P1433
P1476
Bone health and human immunodeficiency virus infection.
@en
P2093
Jason J Schafer
Kathleen E Squires
Kristine Manlangit
P2860
P304
P356
10.1002/PHAR.1257
P407
P577
2013-04-01T00:00:00Z